EXICURE INC (XCUR) Stock News

NASDAQ:XCUR - Nasdaq - US30205M3097 - Common Stock - Currency: USD

6.4 -0.15 (-2.29%)

After market: 6.46 +0.06 (+0.94%)

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

XCUR Latest News, Press Relases and Analysis

All

Press Releases

18 days ago - By: Chartmill - Mentions: PBM ADIL AACG OTRK ...

News Image

What's going on in today's after hours session

9 days ago - By: Benzinga - Mentions: OMI SLRX REPL TLRY ...

12 Health Care Stocks Moving In Monday's Pre-Market Session

12 days ago - By: The Motley Fool

Exicure Posts Wider Loss in Fiscal Q2

12 days ago - By: Exicure, Inc.

Exicure, Inc. Reports Second Quarter 2025 Financial Results

16 days ago - By: Exicure, Inc.

Exicure, Inc. (Nasdaq: XCUR) Regains Compliance with Nasdaq Filing Requirements

18 days ago - By: Benzinga - Mentions: PBM EQ PRPH NSPR ...

12 Health Care Stocks Moving In Friday's After-Market Session

19 days ago - By: Exicure, Inc.

Exicure Completes the Last Patient, Last Visit in Phase 2 Study of GPC-100 for Stem Cell Mobilization in Multiple Myeloma Patients Undergoing Autologous Transplant

2 months ago - By: Exicure, Inc.

Exicure, Inc. Reports First Quarter 2025 Financial Results

3 months ago - By: Exicure, Inc.

Exicure, Inc. Received Nasdaq Delinquency Notice on Late Filing of its Form 10-Q

4 months ago - By: Exicure, Inc.

Exicure Completes Patient Enrollment in Phase 2 Study of GPC-100 for Stem Cell Mobilization in Multiple Myeloma Patients Undergoing Autologous Transplant

4 months ago - By: Yahoo Finance - Mentions: TSLA NVDA AAPL

Why Exicure Inc. (XCUR) Soared on Monday

4 months ago - By: Exicure, Inc.

Exicure, Inc. (Nasdaq: XCUR) Nears Completion of Phase 2 Study of GPC-100 in Multiple Myeloma

4 months ago - By: Exicure, Inc.

Exicure, Inc. (Nasdaq: XCUR) Announces Their Next Step in Planning for a New Clinical Trial in Acute Myeloid Leukemia (AML)

5 months ago - By: Exicure, Inc.

Exicure, Inc. Reports Full Year 2024 Financial Results

5 months ago - By: Exicure, Inc.

Exicure, Inc. (Nasdaq: XCUR) Announces Issuance of New Patent in Australia

7 months ago - By: Exicure, Inc.

CORRECTING and REPLACING Exicure, Inc. Announces Purchase Agreement with GPCR Therapeutics Inc.

8 months ago - By: Exicure, Inc.

Exicure, Inc. Partners with GPCR Therapeutics to Fuel New Growth in Biotech

8 months ago - By: Exicure, Inc.

CORRECTING and REPLACING Exicure, Inc. Announces Shareholders Approve the $8.7 Million Equity Financing and Reports Executive Management and Board Changes